TH6016B - An appropriate vaccine for the prevention and control of disease among haemophilus pluronucleus (Haemophilus). pleuropneumoniae), as well as extracellular protein isolation methods of the hemophilus pluronucleus. Which is suitable for use in vaccines - Google Patents

Abstract

The invention relates to a vaccine suitable for prophylaxis and disease control, respectively, of hemophilus fluoronucleus E. Haemophilus pleuropneumonia. This is a vaccine that works for all serotypes of hemophilus plurophilus pluronemonie. This vaccine has The basic constituents are the effective constituents of a mixture of substances. such as proteins that the germ produces outside the cell which is obtained from food cultured hemophilus Pluronium E. Species with at least two different serotypes, preferably prepared from a culture medium, at least one hemophilus pluronemonie, selected from a group of serotypes. 1, 5, 6, 9 and 11, and the other is prepared from at least one strain of Emophilus pluronumenee, which Choose from a group of serotypes 2,3, 4 and 8 patent drugs.

Claims (6)

1. A generic vaccine suitable for the treatment and control of Haemophilus. pleuropneumonia Among which are characterized by being in The resulting component consists of a mixture of proteins that Extracellular release derived from the culture medium of H. pleuropnerumonia. At least one of the species selected from Serotyp groups 1,5,6,9 and 11 on one side and extracellular emission proteins derived from the culture medium of H. pleuropnerumonai. At least one of the species selected from Zero-type groups 2,3,4 and 8 on the other side. 2. Method for vaccine preparation pursuant to claim 1 characterized by a) breeding of H. pleuropnerumonai was selected from zerotypes 1,2,3,4,5,6,8,9 and 11 on the added culture medium. With nicotinamide adenine dinucleotide (NAD) b) microbial transfusion and culture H. pleuropnerumonai obtained in (a) into serum-rich culture media and / or NAD-free serum products c) sterilized the food by filtering it to obtain a filtrate containing Extracellular emission proteins and d) include extracellular emission proteins derived from the H. pleuropnerumonai strain. At least one of the species selected from Serotypes 1,5,6,9 and 11 on one side and from H. pleuropnerumonai strains. At least one of the culled species Choose from a group of zerotypes 2,3,4 and 8 on the other side. 3. The method of claim 2 characterized by the curing described in steps (a) and / or (b) is performed at a temperature range of 30 to 40 ° C, preferably 37 ° C. 4. Method for processing the filtrate obtained according to the method of claim 2 or 3 showing the characteristics of 1) concentrates the filtrate of interest, for example by mixing it with a solution. That contains salt, for example At least with 50% solution by weight of ammonium sulfate to form flocculant, 2) dissolve the sludge obtained in steps (1) in phosphate buffered celine (PBS) solution and 3) dialized product obtained in ( 2) with BPS is a protein that Through dielectric 5. Method according to claim 4, which characterizes that in step (1), a saturated solution of ammonium sulfate was used. 6. A vaccine suitable for therapy and control. H. pleuropnerumonai in pigs shown in a manner by contribution The resulting compound consists of a mixture of proteins that are released. Extracellular derivatives of the strain culture medium H. pleuropnerumonai At least one of the species selected from Serotypes 1,5,6,9 and 11 on one side and at least one species of H. pleuropnerumonai Selected from Serotyp groups 2,3,4 and 8 on the other hand, by protein, are obtained by means of one or more of the claims 2 - 5 (6 claims, 2 pages, 4 figures).